Clarity Pharmaceuticals Ltd (ASX:CU6 – Get Free Report) insider Rosanne Robinson bought 178,079 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average price of A$0.93 ($0.63) per share, with a total value of A$165,079.23 ($111,540.02).
Clarity Pharmaceuticals Price Performance
Clarity Pharmaceuticals Company Profile
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.
See Also
- Five stocks we like better than Clarity Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- The Average 401k Balance by Age Explained
- When to Sell a Stock for Profit or Loss
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 5 discounted opportunities for dividend growth investors
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Clarity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
